Venetoclax
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell
Trial Timeline
Sep 3, 2018 → Oct 15, 2025
NCT ID
NCT03567876About Venetoclax
Venetoclax is a phase 2 stage product being developed by AbbVie for Lymphoma, Mantle-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT03567876. Target conditions include Lymphoma, Mantle-Cell.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Mantle-Cell were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03123029 | Pre-clinical | Active |
| NCT07387471 | Phase 2 | Recruiting |
| NCT06742086 | Phase 1 | Completed |
| NCT06070948 | Phase 1 | Withdrawn |
| NCT05768711 | Phase 2 | Active |
| NCT05701215 | Phase 2 | Active |
| NCT05909553 | Phase 1 | Completed |
| NCT04810598 | Phase 1 | Completed |
| NCT03844048 | Phase 3 | Active |
| NCT03873857 | Pre-clinical | Completed |
| NCT03567876 | Phase 2 | Completed |
| NCT03485547 | Phase 1 | Completed |
| NCT02966756 | Phase 2 | Recruiting |
| NCT02980731 | Phase 3 | Completed |
| NCT02756611 | Phase 3 | Completed |
| NCT02141282 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, Mantle-Cell